Conversation

EQS-News: Direct Communication Solutions Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering and Application for Uplisting to NYSE American

Retrieved on: 
Friday, December 2, 2022

San Diego, California--(Newsfile Corp. - December 1, 2022) - Direct Communication Solutions, Inc. (OTCQX: DCSX) (CSE: DCSI) (FSE: 7QU) (the "Company", "Direct Communication Solutions" or "DCS"), a leading provider of information technology solutions for the Internet of Things (IoT) market, is pleased to announce that DCS has publicly filed a registration statement with the Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its Common Stock in the United States (the "Offering"). The Offering is expected to take place after the SEC completes its review process, subject to market and other customary conditions. DCS has applied to list its Common Stock on the NYSE American exchange under the ticker symbol "DCSX". The completion of the Offering is contingent upon approval of listing of the Common Stock on the NYSE American exchange and there can be no assurance that such approval will be granted.

Key Points: 
  • The Offering is expected to take place after the SEC completes its review process, subject to market and other customary conditions.
  • DCS has applied to list its Common Stock on the NYSE American exchange under the ticker symbol "DCSX".
  • A registration statement relating to the proposed sale of these securities has been filed with the SEC but has not yet become effective.
  • Securities offered under the registration statement may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

Goodfood Achieves Significant Gross Margin Expansion, Improves Adjusted EBITDA(1) by 89% Year-over-Year and Reaffirms Expectation of Positive Adjusted EBITDA(1) in First Half of FY2023

Retrieved on: 
Friday, December 2, 2022

Goodfoods core purpose is to create experiences that spark joy and help our community live longer on a healthier planet.

Key Points: 
  • Goodfoods core purpose is to create experiences that spark joy and help our community live longer on a healthier planet.
  • As a result, we are reconfirming our expected path to return to positive quarterly Adjusted EBITDA1 in the first half of 2023 with continued growth thereafter.
  • Adjusted gross margin is defined as the percentage of adjusted gross profit to net sales.
  • EBITDA, Adjusted EBITDA & Adjusted EBITDA margin: EBITDA is defined as net income or loss before net finance costs, depreciation and amortization and income taxes.

Direct Communication Solutions, Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering and Application for Uplisting to NYSE American

Retrieved on: 
Thursday, December 1, 2022

San Diego, California--(Newsfile Corp. - December 1, 2022) - Direct Communication Solutions, Inc. (OTCQX: DCSX) (CSE: DCSI) (FSE: 7QU) (the "Company", "Direct Communication Solutions" or "DCS"), a leading provider of information technology solutions for the Internet of Things (IoT) market, is pleased to announce that DCS has publicly filed a registration statement with the Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its Common Stock in the United States (the "Offering"). The Offering is expected to take place after the SEC completes its review process, subject to market and other customary conditions. DCS has applied to list its Common Stock on the NYSE American exchange under the ticker symbol "DCSX". The completion of the Offering is contingent upon approval of listing of the Common Stock on the NYSE American exchange and there can be no assurance that such approval will be granted.

Key Points: 
  • The Offering is expected to take place after the SEC completes its review process, subject to market and other customary conditions.
  • DCS has applied to list its Common Stock on the NYSE American exchange under the ticker symbol "DCSX".
  • A registration statement relating to the proposed sale of these securities has been filed with the SEC but has not yet become effective.
  • Securities offered under the registration statement may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

Direct Communication Solutions Announces Q3 Financials and Strong Revenue Growth

Retrieved on: 
Thursday, December 1, 2022

For the quarter ending September 30, 2022, ("Q3 2022") revenues were USD $4.7 million, versus USD $2.8 million in Q3 2021 (September 30, 2021) representing an increase of 68%.

Key Points: 
  • For the quarter ending September 30, 2022, ("Q3 2022") revenues were USD $4.7 million, versus USD $2.8 million in Q3 2021 (September 30, 2021) representing an increase of 68%.
  • For the quarter ending September 30, 2022, ("Q3 2022") gross profit was USD $1.2 million, versus USD $0.8 million in Q3 2021 (September 30, 2021) representing an increase of 50%.
  • The nine months gross profit ending Q3 2022, was reported at USD $5.7 million versus USD $3 million in 2021 representing an increase of 90%.
  • The nine months Adjusted EBITDA ending Q3 2022 was reported at USD $1.6 million versus a loss of USD $1.4 million in 2021, representing an increase of USD $3.0 million.

NUROSENE BUSINESS UPDATE

Retrieved on: 
Thursday, December 1, 2022

TORONTO, Dec. 1, 2022 /PRNewswire/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry, is pleased to share the following business update.

Key Points: 
  • TORONTO, Dec. 1, 2022 /PRNewswire/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry, is pleased to share the following business update.
  • The opportunity At Nurosene, we believe there is a significant opportunity to address the very low rate of success in the clinical trial process, by using the NetraAI technology.
  • Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
  • New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors.

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Retrieved on: 
Thursday, December 1, 2022

ADX-2191, which has received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma, is a novel, vitreous-compatible formulation of methotrexate.

Key Points: 
  • ADX-2191, which has received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma, is a novel, vitreous-compatible formulation of methotrexate.
  • ADX-2191 has received FDA Orphan Drug Designation for the prevention of proliferative vitreoretinopathy, and the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
  • Primary vitreoretinal lymphoma is a rare, aggressive, and potentially fatal retinal cancer that is diagnosed in approximately 300 to 600 patients in the United States per year.
  • Data on file; Primary Vitreoretinal Lymphoma by D. J. Wilson on AAO EyeWiki; M. Sagoo, Survey of Ophthalmology (2014); Grimm et.

VoiceFoundry Achieves AWS Conversational AI Competency

Retrieved on: 
Thursday, December 1, 2022

Achieving the AWS Conversational AI Competency differentiates VoiceFoundry as an AWS Partner Network (APN) member with significant domain expertise in deploying high quality, highly effective conversational-AI solutions to improve customer experiences.

Key Points: 
  • Achieving the AWS Conversational AI Competency differentiates VoiceFoundry as an AWS Partner Network (APN) member with significant domain expertise in deploying high quality, highly effective conversational-AI solutions to improve customer experiences.
  • Attaining the AWS Conversational AI Competency, demonstrates to our customers that VoiceFoundry has validated expertise in Conversational AI on AWS.
  • "VoiceFoundry is proud to achieve the AWS Conversational AI Competency," said Cliff Wiser, Vice President of Sales Engineering at VoiceFoundry.
  • To support the seamless integration and deployment of these solutions, AWS established the AWS Competency Program to help customers identify AWS Partners with deep industry experience and expertise.

Mission Accomplished: Canoo Delivers Light Tactical Vehicle to Army for Analysis & Demonstration

Retrieved on: 
Thursday, December 1, 2022

JUSTIN, Texas, Dec. 1, 2022 /PRNewswire/ -- Canoo (NASDAQ: GOEV), a leading high-tech advanced mobility company, has delivered its new Light Tactical Vehicle (LTV) to the United States Army for Analysis & Demonstration in fulfilment of the contract awarded in July 2022.

Key Points: 
  • "The LTV is another milestone proving the power of our technology," said Tony Aquila, Chairman & CEO at Canoo.
  • As with all Canoo vehicles, the LTV is designed for passenger ergonomics, taking body motion and height into consideration as well as multi-taskcomponents.
  • "The LTV is another milestone proving the power of our technology and how it can be used, even in tactical situations," said Tony Aquila, Chairman & CEO at Canoo.
  • Modular for Multiple Use Cases: Convertible Flatbed, Mounting Racks, Ramps & Tactical Systems
    A jack-of-all trades, the Light Tactical Vehicle can be converted from a pickup to a flatbed truck, a cargo vehicle and more.

BlueRush Announces Strong Fiscal 2022 Year End Financial Results

Retrieved on: 
Thursday, December 1, 2022

TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- BlueRush Inc. ("BlueRush" or the "Company") (TSXV:BTV; OTCQB:BTVRF), a leading personalized video Software as a Service ("SaaS") company, today announced its financial results for the three months and year ended July 31, 2022, which were marked by strong growth and impressive margins.

Key Points: 
  • TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- BlueRush Inc. ("BlueRush" or the "Company") (TSXV:BTV; OTCQB:BTVRF), a leading personalized video Software as a Service ("SaaS") company, today announced its financial results for the three months and year ended July 31, 2022, which were marked by strong growth and impressive margins.
  • Fiscal 2022 was also a transitional year for BlueRush, as we developed an extension to our SaaS IndiVideo platform.
  • This allows us to expand our target market to include smaller companies and we anticipate will help shorten our sales cycles, said Steve Taylor, CEO of BlueRush.
  • Financial highlights for year ended July 31, 2022 as compared to the same period in 2021 include 91.4% SaaS gross margin.

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)

Retrieved on: 
Thursday, December 1, 2022

clonoSEQ can assess a patients MRD status in DLBCL by measuring ctDNA, the fragments of DNA released into the blood from dying cancer cells which can serve as a measure of tumor burden.

Key Points: 
  • clonoSEQ can assess a patients MRD status in DLBCL by measuring ctDNA, the fragments of DNA released into the blood from dying cancer cells which can serve as a measure of tumor burden.
  • clonoSEQ MRD testing is covered by Medicare in DLBCL, with coverage extending to all DLBCL patients regardless of line of therapy, treatment regimen, or testing timepoint.
  • clonoSEQ is the first and only MRD test to receive Medicare coverage in DLBCL.
  • Robust peer-reviewed evidence supports the use of clonoSEQ as a powerful blood-based prognostic tool in DLBCL.